OBJECTIVE: To examine the effects of reduction in dietary sodium intake on cardiovascular events using data from two completed randomised trials, TOHP I and TOHP II. DESIGN: Long term follow-up assessed 10-15 years after the original trial. SETTING: 10 clinic sites in 1987-90 (TOHP I) and nine sites in 1990-5 (TOHP II). Central follow-up conducted by post and phone. PARTICIPANTS: Adults aged 30-54 years with prehypertension. INTERVENTION: Dietary sodium reduction, including comprehensive education and counselling on reducing intake, for 18 months (TOHP I) or 36-48 months (TOHP II). MAIN OUTCOME MEASURE: Cardiovascular disease (myocardial infarction, stroke, coronary revascularisation, or cardiovascular death). RESULTS:744 participants in TOHP I and 2382 in TOHP II were randomised to a sodium reduction intervention or control. Net sodium reductions in the intervention groups were 44 mmol/24 h and 33 mmol/24 h, respectively. Vital status was obtained for all participants and follow-up information on morbidity was obtained from 2415 (77%), with 200 reporting a cardiovascular event. Risk of a cardiovascular event was 25% lower among those in the intervention group (relative risk 0.75, 95% confidence interval 0.57 to 0.99, P=0.04), adjusted for trial, clinic, age, race, and sex, and 30% lower after further adjustment for baseline sodium excretion and weight (0.70, 0.53 to 0.94), with similar results in each trial. In secondary analyses, 67 participants died (0.80, 0.51 to 1.26, P=0.34). CONCLUSION: Sodium reduction, previously shown to lower blood pressure, may also reduce long term risk of cardiovascular events.
RCT Entities:
OBJECTIVE: To examine the effects of reduction in dietary sodium intake on cardiovascular events using data from two completed randomised trials, TOHP I and TOHP II. DESIGN: Long term follow-up assessed 10-15 years after the original trial. SETTING: 10 clinic sites in 1987-90 (TOHP I) and nine sites in 1990-5 (TOHP II). Central follow-up conducted by post and phone. PARTICIPANTS: Adults aged 30-54 years with prehypertension. INTERVENTION: Dietary sodium reduction, including comprehensive education and counselling on reducing intake, for 18 months (TOHP I) or 36-48 months (TOHP II). MAIN OUTCOME MEASURE: Cardiovascular disease (myocardial infarction, stroke, coronary revascularisation, or cardiovascular death). RESULTS: 744 participants in TOHP I and 2382 in TOHP II were randomised to a sodium reduction intervention or control. Net sodium reductions in the intervention groups were 44 mmol/24 h and 33 mmol/24 h, respectively. Vital status was obtained for all participants and follow-up information on morbidity was obtained from 2415 (77%), with 200 reporting a cardiovascular event. Risk of a cardiovascular event was 25% lower among those in the intervention group (relative risk 0.75, 95% confidence interval 0.57 to 0.99, P=0.04), adjusted for trial, clinic, age, race, and sex, and 30% lower after further adjustment for baseline sodium excretion and weight (0.70, 0.53 to 0.94), with similar results in each trial. In secondary analyses, 67 participants died (0.80, 0.51 to 1.26, P=0.34). CONCLUSION:Sodium reduction, previously shown to lower blood pressure, may also reduce long term risk of cardiovascular events.
Authors: R Stamler; J Stamler; F C Gosch; J Civinelli; J Fishman; P McKeever; A McDonald; A R Dyer Journal: JAMA Date: 1989-10-06 Impact factor: 56.272
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2011-12-15 Impact factor: 29.690
Authors: Cheryl A M Anderson; Lawrence J Appel; Nagako Okuda; Ian J Brown; Queenie Chan; Liancheng Zhao; Hirotsugu Ueshima; Hugo Kesteloot; Katsuyuki Miura; J David Curb; Katsushi Yoshita; Paul Elliott; Monica E Yamamoto; Jeremiah Stamler Journal: J Am Diet Assoc Date: 2010-05
Authors: I Drenjančević-Perić; B Jelaković; J H Lombard; M P Kunert; A Kibel; M Gros Journal: Kidney Blood Press Res Date: 2010-11-12 Impact factor: 2.687
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-12-15 Impact factor: 29.690
Authors: Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers Journal: Endocrinol Metab Clin North Am Date: 2013-12-12 Impact factor: 4.741
Authors: Jiang He; Katherine T Mills; Lawrence J Appel; Wei Yang; Jing Chen; Belinda T Lee; Sylvia E Rosas; Anna Porter; Gail Makos; Matthew R Weir; L Lee Hamm; John W Kusek Journal: J Am Soc Nephrol Date: 2015-09-17 Impact factor: 10.121